



Published in final edited form as:

BJOG. 2011 April ; 118(5): 533–549. doi:10.1111/j.1471-0528.2010.02840.x.

The vaginal microbiome: New information about genital tract flora using molecular based techniques

Ronald F. Lamont, BSc, MB, ChB, MD, FRCOG^{1,2}, Jack D. Sobel, MD³, Robert A. Akins, PhD⁴, Sonia S. Hassan, MD^{1,2}, Tinnakorn Chaiworapongsa, MD^{1,2}, Juan Pedro Kusanovic, MD^{1,2}, and Roberto Romero, MD^{1,2,5}

¹Perinatology Research Branch, NICHD, NIH, DHHS, Bethesda, Maryland and Detroit, Michigan, USA

²Department of Obstetrics and Gynecology, Wayne State University/Hutzel Hospital, Detroit, Michigan, USA

³Department of Infectious Diseases, Wayne State University/Hutzel Hospital, Detroit, Michigan, USA

⁴Department of Biochemistry & Molecular Biology, Wayne State University Medical School, Detroit, Michigan, USA

⁵Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA

Abstract

Vaginal microbiome studies provide information which may change the way we define vaginal flora. Normal flora appears dominated by one or two species of *Lactobacillus*. Significant numbers of healthy women lack appreciable numbers of vaginal lactobacilli. Bacterial vaginosis (BV) is not a single entity, but different bacterial communities or profiles of greater microbial diversity than is evident from cultivation-dependent studies. BV should be considered a syndrome of variable composition which results in different symptoms, phenotypical outcomes, and responses to different antibiotic regimens. This information may help to elucidate the link between BV and infection-related adverse outcomes of pregnancy.

INTRODUCTION

In normal pregnancy, the resident vaginal microbial flora is thought to provide protection against infection by a number of different mechanisms.¹ In non-pregnant women, the presence of bacterial vaginosis (BV) is associated with an increased risk of upper genital tract and sexually transmitted infections²⁻⁴ and acquisition of HIV.⁵⁻⁹ In pregnancy, BV increases the risk of post-abortal sepsis,¹⁰ early miscarriage¹¹ recurrent abortion,¹² late miscarriage,^{12;13} preterm prelabor rupture of membranes (PPROM),¹⁴ spontaneous preterm labor (SPTL) and preterm birth (PTB),^{13;15-26} histological chorioamnionitis^{27;28} and postpartum endometritis.^{29;30} As a result, abnormal vaginal flora may predispose to ascending colonization of the genital tract, infiltration of the fetal membranes, microbial invasion of the amniotic cavity³¹ and fetal damage.^{32;33} Preterm birth of infectious etiology

Corr. Author rlamont@med.wayne.edu.

Contribution to authorship – all authors have contributed

Details of ethics approval and Funding – not applicable

Disclosure of interests - None

is associated with high perinatal mortality and morbidity,³⁴⁻³⁶ and a high cost to the healthcare system.³⁷⁻³⁹ Much of our knowledge about the composition of the vaginal microbial flora comes from qualitative and semi-quantitative descriptive studies using cultivation-dependant techniques.⁴⁰⁻⁴⁴ In recent years, the development and introduction of cultivation-independent molecular-based techniques have provided new information about the composition of normal vaginal flora as well as abnormal colonization of the genital tract which complements existing knowledge from cultivation-dependent techniques. This review seeks to inform the busy obstetrician about the background to these new developments and what additional information they provide. These new data might help to elucidate the composition and function of normal flora, and appreciate the microbial diversity, diagnosis, and treatment assessment of abnormal genital tract flora which may affect the outcome of pregnancy.

THE HUMAN MICROBIOME PROJECT

During the conduct of the human genome project, scientists estimated that the number of genes in the human genome that would be needed to code for the proteins required to sustain human physiology, would be approximately 100,000. The researchers were somewhat humbled to find only 20,000 protein coding genes, similar to that of the fruit fly. However, if one considers the human to be a super-organism, (the sum of all human genes plus those of the micro-organisms in, or on us), then the human genome plus the microbial genome [microbiome] which amounts to the collective genome of the symbionts may be considerably more than 100,000 genes. This is supported by the fact that the human microbiome provides traits which the human organism has not needed to evolve for itself.^{45;46} The NIH in its roadmap for medical research has committed \$100,000,000 to the Human Microbiome Project and plans to investigate five sites – the oral and nasal cavities, the gastrointestinal and genito-urinary tracts and the skin. The genital tract microbiome will be studied in health and disease and whether the function of the microbiome (metagenome) can be manipulated to influence physiology and treat disease. The core microbiome, as well as the variable microbiome (influenced *inter alia* by host lifestyle, genotype, immune response, environment, pathophysiology and transient community members) will be assessed spatially and temporally,⁴⁷ and different sub-sites will be assessed. The microbial flora on the labial surface of the teeth are different from those on the lingual surface,⁴⁸ and the lower vagina, upper vagina and cervix also differ in their microbial flora.⁴⁹ How this relates to the various niches in the female genital tract in pregnancy and to the human microbiome project as a whole is indicated in Figure 1.

MICROBIAL TAXONOMY

Cultivation-independent techniques require us to be aware of different levels of taxonomic classification. Taxonomy is the classification of living organisms into phylogenetic groups. Phylogenetic classifications arrange organisms into groups which reflect genetic similarity and evolutionary relatedness. A taxon is a group, or level of classification, and is hierarchical, whereby broad divisions are divided up into smaller divisions such as Domains, Kingdoms, Phyla, Classes, Orders, Families, Genera, and Species. Not every level is used in every discipline. The species is the basic unit of taxonomy and many molecular based studies use different terms such as “operational taxonomic units”, “taxons/taxa” or “phylotypes” instead of species, because the level of molecular diversity far outstrips that defined by existing microbiological or biochemical means. The human intestine demonstrates the greatest degree of diversity with over 400 phylotypes only 20% of which are cultivatable.⁵⁰

MOLECULAR BASED TECHNIQUES

Many of the culture-independent studies focus on the detection of novel, previously uncultivated species⁵¹⁻⁵⁶ or are more concerned with the novel molecular techniques in themselves rather than for the microbiological information they provide.⁵⁷⁻⁶⁰ In addition, theoretical and mathematical models have arisen which address new concepts such as “functional redundancy,” “structural diversity,” “interspecies interaction,” “mutualism,” “cheating,” “the insurance hypothesis,” “drivers” and “passengers”.⁶¹⁻⁶⁴

Bacterial DNA is extracted from samples, and is amplified using the polymerase chain reaction (PCR) using either universal or specific primers. This is not infallible because PCR inhibitors may be present at varying levels in individual clinical samples, and primers may preferentially amplify certain nucleic acids, and may not complement the entire bacterial kingdom.⁶⁵

The commonest target for molecular identification of bacteria is the small ribosomal subunit of the 16S rRNA gene. The 16S rRNA gene is useful because it is present in all bacteria and has regions of conserved sequence which can be targeted by universal (sometimes referred to as bacterial-domain or broad-range primers) or specific primers, yet also has areas of heterogeneity which can be used to identify bacteria or to infer phylogenetic relationships.⁶⁶⁻⁷¹ If there is uncertainty with respect to which organisms might be present in a sample or if a broad diversity of organisms are anticipated, then many researchers will use universal primers.⁵³ If, on the other hand, an investigator knows what organisms to expect, or wishes to test for specific organisms then specific primers will be used.⁷² Once the 16S rRNA gene has been sequenced, the variable regions can be used for species specific PCR in a qualitative or quantitative manner. The sequences obtained are aligned and compared with large databases of 16S rRNA sequences, although diversity for vaginal microbial flora is poorly represented in these databases compared to other sites like the gastro-intestinal tract.^{54;60}

Cultivation-based studies have the disadvantage that they may fail to isolate or detect large numbers of fastidious micro-organisms, or identification tests may not be available. An unknown number of species which are identified purely by molecular methods are culturable, but have not been identified by cultivation methods because of a lack of phenotypic tools for the species, their lower relative titers, or inappropriate media (REF: Rabe LK, Antonio M, Austin MA, Stoner K, Pollard R, Petrina M, Leyland B, Chaiworapongsa T, Lamont RF, Hassan S, Romero R, and Hillier S. A 21st Century Description of the Vaginal Microflora of Pregnant Women. Proceedings of the Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology, Santa Fe, New Mexico, USA, Aug 6th 2010.

This is an important distinction, since it shifts the focus of new research from developing novel culture media to using molecular tools to identify the under-characterized colonies that already grow in current formulations. This also restricts the development of their phenotypic profiles and hence the understanding of their roles in the whole population. In addition, this suggests that before the development of molecular techniques, culture-based assessments of the vaginal microbiome did not “miss” 80% of the species, but simply had no labels to impose on many colonies. As a result these organisms were included only as members belonging to a broad phenotypic or phylogenetic branch.

Cultivation-independent techniques may show greater diversity by overcoming cultivation problems with and identification of fastidious organisms, but are limited by their tendency to sample only the most prevalent bacteria in a community, such that low abundance or minority species are likely to be missed.⁷³ Since PCR amplification of DNA is a competitive

enzymatic reaction, the 16S rRNA templates in a sample are amplified in accordance with their abundance. As a result, the 16S rRNA genes of the numerically dominant population will be the most abundant amplicons following PCR. Populations that constitute <1% of the total community (yet may still be present in >10⁶/g of vaginal fluid) may not be represented in such profiles, so this represents the threshold of detection. This being the case, despite their limitations, cultivation studies remain an important part of vaginal microbiology and will need to be used in combination with cultivation-independent techniques.⁷⁴ The development of the next generation of ultra-high throughput sequencing technologies (pyrosequencing) may remove an important quantitative barrier by increasing the number of reads from a gene or genome by many orders of magnitude in one experimental run.⁷⁵ The power of next generation sequencing, however, is not without limitations. Until recently, error rates using pyrosequencing were high enough to generate reading errors that generated false microdiversity at the species or subspecies levels. However, improvements in the technology in 3rd generation systems now produces sequencing with error rates similar to Sanger sequencing, which should minimize this in future experiments. Even this improvement does not overcome the best read lengths among these, (~ 350-400 bases). The variable domains of 16S rDNA, which allow best species discrimination, are spread out over >1kb, so only some can be captured in this run length. This limits discrimination to the genus level for some phylogenetic branches with minimal diversity at this locus.⁷⁶ This obstacle remains a stumbling block for most of the next generation sequencing methods, less so as read lengths are steadily improving via technical advancements. For an insight into the pros and cons of the various techniques and their limitations the reader is directed to three excellent reviews.⁷⁷⁻⁷⁹

NORMAL VAGINAL FLORA

Most studies, whether cultivation-dependent or independent, give the impression that the vaginal microbial flora is static, because most studies are carried out as a “snap-shot” in time and do not consider that vaginal microbial communities undergo shifts in their representation, abundance and virulence over time, and are affected by many factors.

Identification of Lactobacilli to the Species Level Using Molecular-based Techniques

Culture and microscopy of “normal” vaginal flora typically shows a predominance of *Lactobacillus* species which are believed to promote a healthy vaginal milieu by providing numerical dominance but also by producing lactic acid to maintain an acid environment that is inhospitable to many bacteria and is negatively correlated with BV.⁸⁰ Lactobacilli also produce hydrogen peroxide (H₂O₂),⁸¹ antibiotic toxic hydroxyl radicals, bacteriocins,⁸² and probiotics.⁸³ Prior to molecular-based techniques, lactobacilli were generally identified only to the genus level.

In 1892, Professor Albert Döderlein (1860-1941) published his definitive monograph in which he recorded that cultured organisms were a source of lactic acid which could inhibit the growth of pathogens *in vitro* and *in vivo*.⁸⁴ In 1928, Stanley Thomas identified Doderlein's bacillus as *Lactobacillus acidophilus*, adding prophetically, that this was either a characteristic group of related species, or a species which underwent a remarkable transformation.⁸⁵ In 1980, in keeping with the observation of Thomas, a group of organisms previously collectively known as *L. acidophilus* was shown to be highly heterogeneous.⁸⁶ As a result, the group was divided into DNA homologous groups that could not be distinguished biochemically,⁸⁷ to form a number of separate species within the *L. acidophilus* complex (Table 1).⁸⁸⁻⁹⁰ The closely related species within the *L. acidophilus* complex are difficult to differentiate by phenotypic methods which may account for the variation in species of lactobacilli found in different studies.⁹¹⁻⁹³

Cultivation-based techniques, because they fail to detect fastidious organisms, underestimate the diversity of vaginal microbial flora, but because of deficiencies in the phenotypic identification of lactobacilli they overestimate the diversity of *Lactobacillus* species in the vagina.⁹⁴

Some 20 years ago, using cultivation-based phenotypic techniques, Redondo-Lopez et al concluded that no two women were colonized by the same two *Lactobacillus* species.⁹² Using cultivation-independent techniques this would appear now not to be the case and because of their significant role in health and disease, there has been much attention to the identification of lactobacilli using genotypic means.^{51;65;91;95-98}

***Lactobacillus iners*: under-detected and under-appreciated**

The existence of *Lactobacillus iners* was unknown prior to 1999 but is now known to play a significant role in vaginal microbial flora. Selective media such as Rogosa or MSR agar are normally used to culture lactobacilli, so the use of cultivation-based techniques, even those followed by molecular methods, will not detect *L. iners* because it only grows on blood agar.⁹⁰ Hence, some very important molecular based studies failed to isolate *L. iners* because Rogosa or MRS agar were used rather than blood agar.^{51;95;99-101}

The first report of isolation of *L. iners* in a woman with a normal Nugent score was in 2002.⁶⁵ Cultivation-independent methods have identified *L. iners*, a lactic acid producing bacterium, as one of the organisms most frequently isolated from the vagina of healthy women.^{62;65;97;98;102-104} In contrast to *L. crispatus*, which is rarely dominant in BV,⁵³ *L. iners* can be detected at high levels in most subjects with and without BV,^{53;65;105;106} and in three studies it was the only *Lactobacillus* species detected in BV positive women.^{52;53;105} It has been postulated that this may be because *L. iners* may be better adapted to the conditions associated with BV, i.e. the polymicrobial state of the vaginal flora and elevated pH.¹⁰⁵ Alternatively, the observations could result from relative resistance of *L. iners* to unknown factors that lead to the demise of other *Lactobacillus* species during the onset of BV, or to a relative lack of antagonism of *L. iners* to the BV-associated anaerobes, so that their dominance predisposes the individual to acquiring BV.

Numerical Supremacy of *Lactobacilli*

Over 120 species of *Lactobacillus* have been identified, and more than 20 species have been detected in the vagina. Using molecular-based techniques, we now know that healthy vaginal microflora does not contain high numbers of many different species of *Lactobacillus*. Rather, one or two lactobacilli from a range of three or four species (mainly *L. crispatus* and *L. iners* but also *L. jensenii* and *L. gasseri*) are dominant, whereas other species are rare, lower in titer, and tend to be novel phylotypes.^{51;52;55;62;65;97;100;101;103;106-109}

In healthy Swedish women with a normal Nugent score,¹¹⁰ 202 vaginal isolates were tested against 26 type and reference strains of *Lactobacillus*.⁹⁷ In 18/23 women, the vaginal flora was dominated by a single species of *Lactobacillus* and only five women had two different species or two different strains of the same species of *Lactobacillus*. The only species detected were *L. crispatus*, *L. gasseri*, *L. iners*, and *L. jensenii*.⁹⁷ In a follow up study only one woman was colonized by more than two *Lactobacillus* species, four were colonized by two different species and 17 were colonized by one single species.⁹⁸ Although this study was severely limited by the small number of colonies examined per patient (10 from blood, 100 from Rogosa agar), the exclusion of other species is in keeping with the theory of “competitive exclusion”⁵⁵ and the superior ability of *L. iners* and *L. crispatus* to compete with other bacteria for vaginal resources, a survival strategy known as “bacterial

interference".¹¹¹ Alternatively, the rare co-existence of multiple dominant species of *Lactobacillus* could be due to pre-emptive colonization by a particular species, or due to host factors that strongly influence which species are able to colonize the environment.

Cultivation-independent studies using molecular techniques have been published on different populations such as adolescent girls,⁵⁵ post menopausal women^{65;112} and women from Belgium,^{52;107;109} Brazil,¹¹³ Bulgaria,⁹⁴ Canada,^{57;65;112} China,¹⁰⁸ Germany,¹⁰⁶ Holland,¹¹⁴ India,¹¹⁵ Italy,⁹⁹ Japan,^{100;116} Nigeria,^{102;117} Sweden,^{97;98} both Turkey and the USA,¹¹⁸ the USA,^{54;55;58;62;95;103} African-American women,¹⁰⁵ Caucasian and black North American women¹⁰³ and a multinational group of women from seven different countries.⁵¹

Racial variation and geographical area are important⁵¹ and different racial groups within the same geographical region have significant differences in what is the dominant vaginal organism.¹⁰³ In most populations, *L. crispatus* is the commonest dominant isolate, 51-53;58;62;97;103;104 and white women are more likely to be dominated by *L. crispatus* and/or *L. jensenii* than any other species of *Lactobacillus*.⁹⁵ A number of genetic as well as environmental factors might explain at least in part this observation. Alternatively, diet might influence the *Lactobacillus* species resident in the gastro-intestinal tract and hence the vagina since the lactobacilli of the gut varies between Japanese and Western subjects.¹¹⁹⁻¹²¹

Production of H₂O₂ by Lactobacilli and the Association with Bacterial Vaginosis

Lactobacilli differ in their ability to produce H₂O₂ and a reduction in the prevalence and concentration of H₂O₂ producing bacteria is associated with the development of BV and vaginal infections.^{81;122} With the introduction of molecular based techniques, it is now possible to relate the production of H₂O₂ to individual species or strains of the same species of *Lactobacillus* rather than the genus as a whole. Three studies using molecular based techniques have addressed the production of H₂O₂ by lactobacilli.^{95;100;101} In Japanese women who did not have BV, *L. crispatus* and *L. gasseri* were found in the vagina of 52.7% and 20.8% of women respectively. *L. jensenii* was not detected, All strains of *L. crispatus* were strongly positive for H₂O₂, whereas 41% and 59% of *L. gasseri* strains were strongly and weakly positive for H₂O₂ respectively.¹⁰⁰

Antonio et al (1999) demonstrated that *Lactobacillus* species detected among 302 women with and without BV differed in their ability to produce H₂O₂. *L. crispatus* and *L. jensenii* were found to colonize 32% and 23 % of women respectively and 95% and 94% of their strains, respectively, were shown to produce H₂O₂. In contrast, *L. gasseri* and *L. iners* colonized 5% and 15% of women respectively and only 71% and 9% of their strains respectively produced H₂O₂. Not surprisingly, BV was present in 9% and 7% of women colonized by *L. crispatus* and *L. jensenii* respectively, and in 43% and 36% of women colonized by *L. gasseri* and *L. iners* respectively. Of the women without BV by Nugent score,¹¹⁰ 16% had no lactobacilli present, and none of the women colonized by *L. crispatus* and *L. jensenii* had BV; however, the latter argument is circular, since the *Lactobacillus* morphotype is part of the Nugent score. The association between *L. gasseri* and BV has been confirmed in a study of homosexual women. Detection of *L. gasseri* was associated with a 4.2 fold increased risk of BV,¹²³ and attributed to a higher rectal colonization by *L. gasseri* and sexual practices which increase the risk of vaginal colonization from the rectum.¹²⁴

Using culture-based techniques Eschenbach et al¹²² and McGroarty et al¹²⁵ found that 100% of *L. jensenii* produced H₂O₂, yet Nagy et al¹²⁶ found only 46%. Similarly, with *L. acidophilus* the range of species which produced H₂O₂ varied from 43% to 77%.^{122;125;126} This may have been due to the inability of biochemical assays to differentiate between the

species belonging to the *L. acidophilus* complex. However, this led Nagy et al to conclude, that the ability of lactobacilli to produce H₂O₂ was associated with the origin of strain (whether from women with or without BV) rather than the *Lactobacillus* strain itself.¹²⁶ In light of the findings of molecular-based techniques, and the current ability to identify H₂O₂ producing lactobacilli to the species level,⁹⁵ we might alternatively conclude that it is whether or not the strain/species of *Lactobacillus* produces H₂O₂ that dictates whether BV is present or absent. However, given that H₂O₂-producing *L. gasseri* are found in BV patients, albeit at lower incidence, one might also argue that in vitro production of H₂O₂ is only a biomarker of a protective species of *Lactobacillus*, not an active factor in limiting the growth of vaginal anaerobes. Indeed, it is not clear whether bacterial H₂O₂ production is active in the microaerobic to anaerobic vaginal flora. Other factors may include the extent to which a species can dominate numerically over its competitors, e.g. 95% versus 99.99%.

Healthy vaginal flora not dominated by lactobacilli

Using culture-independent techniques several investigators have demonstrated that a significant proportion (7-33%) of healthy women lack appreciable numbers of *Lactobacillus* species in the vagina^{52;58;62;102;103} which may be replaced by other lactic acid producing bacteria such as *Atopobium vaginae*, *Megasphaera* and *Leptotrichia* species.^{62;103} Although the structure of the communities may differ between populations, health can be maintained provided the function of these communities i.e. the production of lactic acid, continues.^{55;62} Consequently, the absence of lactobacilli or the presence of certain organisms such as *G.vaginalis*, or species of *Peptostreptococcus*, *Prevotella*, *Pseudomonas*, and/or *Streptococcus*, does not constitute an abnormal state.⁵⁸ This issue is still unclear, however, because the studies do not address whether some proportion of “healthy” women are patients in transition to or from BV, or whether they have asymptomatic BV, ie. abnormal flora but no symptoms due to genetic or other factors. Indeed, a recent molecular study further confuses the issue by pointing out that *G. vaginalis* may produce transient dominance in healthy women as a result of perturbations such as increase in pH, during menstruation.¹²⁷

Vaginal Probiotic Lactobacilli

The first example of vaginal probiotics use we could detect was that of Stanley Thomas in 1928 following his observation that *Lactobacilli* were absent in the presence of gonococci. He reported on two experiments, one *in-vitro* and the other *in vivo* in which addition of a thin layer of whey broth from a culture of *L. acidophilus* demonstrated eradication of *Neisseria gonorrhoeae*.⁸⁵

Exogenous strains of *Lactobacilli* have been suggested as a means of establishing or re-establishing normal vaginal flora. *L. fermentum* and *L. rhamnosi* probiotic strains have been used with poor results in urogenital infection and this may be because they are not normally prevalent in the vagina.^{104;128;129} In contrast, *L. crispatus* might be a better choice because it is commonly found to be numerically dominant in the healthy vagina and 95% of the strains produce H₂O₂.⁹⁵ *L. crispatus* may have a superior capacity to persist in the vagina¹³⁰ and strains of probiotic *L.crispatus* CTV-05 have been demonstrated to have high mean adherence to vaginal epithelial cells *in vitro*¹³¹ and established vaginal colonization in 7 of 9 women when administered vaginally.¹³² Combined vaginal and rectal colonization by H₂O₂ producing *Lactobacilli* is associated with a four-fold decrease in the incidence of BV.¹³¹

Using molecular based techniques in a double blind, randomized, single centre study of 90 non-pregnant, sexually active women, who were free from genital infection, and had a normal Nugent score, the ability of the probiotic *L. crispatus* CTV-05 to establish vaginal colonization was studied.¹³³ The study demonstrated that *L. crispatus* CTV-05 established

vaginal colonization at one or more follow-up visits in 69% of women overall and 90% of those not already colonized with *L. crispatus*. Of women who were never colonized with *L. crispatus* CTV-05, 85% were already colonized by endogenous *L. crispatus* at enrollment. The authors saw this as self regulatory rather than a shortcoming of the probiotic, and the dosage regimen did not result in overgrowth of *Lactobacilli* since there seemed to be a physiological adjustment to around 10^6 or 10^8 cfu/mL of vaginal fluid. They also recommended that future research should concentrate on *Lactobacilli* which are prevalent in the vagina¹³³ rather than species such as *L. fermentum* and *L. rhamnosus*.

ABNORMAL VAGINAL FLORA

Abnormal vaginal flora may occur because of a sexually transmitted infection (STI) eg trichomoniasis, colonization by an organism which is not part of the normal vaginal community e.g. *Streptococcus pneumoniae*, *Haemophilus influenzae*, or *Listeria monocytogenes*, or by overgrowth or increased virulence of an organism that is a constituent part of normal vaginal flora e.g. *Escherichia coli*. Alterations in vaginal flora do not necessarily imply disease or result in symptoms. Disease results from interplay between microbial virulence, numerical dominance, and the innate and adaptive immune response of the host.¹³⁴ The most common disorder of vaginal flora is BV. BV is a polymicrobial condition, characterized by a decrease in the quality or quantity of *Lactobacilli* and a one thousand-fold increase in the number of other organisms as determined by cultivation-dependent techniques, particularly anaerobes *Mycoplasma hominis*, *Gardnerella vaginalis* and *Mobiluncus* species. The prevalence of BV in pregnancy in the USA is 1,080,000 cases annually.¹³⁵ In pregnancy, BV has been associated with early,¹¹ and late miscarriage,^{12;136} recurrent abortion,¹² post abortal sepsis,¹⁰ post partum endometritis,³⁰ and preterm birth.^{12;21;136-138}

BV and HIV

BV is also associated with acquisition of HIV.⁵⁻⁹ Healthy lactic acid producing vaginal flora acts as a barrier against acquisition of HIV^{139;140} and is negatively correlated with BV⁸⁰ which acts as a co-factor for HIV and conversion to seropositivity.⁵⁻⁹ HIV infected women with BV have higher levels of HIV viral load in genital secretions than do HIV infected women without BV.^{6;141;142} BV is also associated with increased susceptibility to other STIs including herpes simplex virus -2, gonorrhoea, *Trichomonas vaginalis* and *Chlamydia trachomatis*.^{141;143-145} Molecular based studies suggest a trend towards increased diversity in the microbiome of HIV positive women with BV compared to those HIV positive women who do not have BV suggesting that HIV infection *per se* is associated with changes in the diversity of genital microbiota.¹⁴⁶

Individual bacteria as a cause of BV

Many of the models necessary to demonstrate that bacteria function as mono-etiological agents require a change in the micro-environment before an infectious event is observed. Infective peritonitis is easier to induce in experimental animals if blood is instilled into the peritoneal cavity, experimental gangrene develops better if calcium chloride is implanted into muscle along with *Clostridium* species, and rodents will not develop vaginal candidiasis without the addition of estrogen.⁴² In the definitive paper of Gardner and Dukes (1955), the instillation of pure cultures *Haemophilus vaginalis* (now known as *Gardnerella vaginalis*) only successfully induced vaginal colonization in one of 13 volunteers.¹⁴⁷ In contrast, 11 of 15 volunteers were successfully inoculated when the vaginal secretions of donors (screened for other genital tract infections) were instilled into the vagina. This supports the later view of others, that since vaginal secretions from donors were much more successful at causing

disease than pure cultures, *G. vaginalis* probably acts synergistically with other organisms to cause BV.¹⁴⁸

***Atopobium vaginae*: under-detected and under-appreciated**

The genus *Atopobium* lies within the family *Coriobacteriaceae* and forms a distinct branch within the phylum *Actinomycetes*.¹⁴⁹ Following sequence analysis, three species formally designated *Lactobacillus minutus*,¹⁵⁰ *Lactobacillus rimae*,¹⁵¹ and *Streptococcus parvulus*¹⁵² within the lactic acid producing group of bacteria,¹⁵³ have been reclassified as genus *Atopobium*. In 1999, an organism similar but not identical to these three species was isolated from the vagina of a healthy woman in Sweden and the organism was named *Atopobium vaginae*.¹⁵⁴ Since that time, using molecular-based techniques, *A. vaginae* has frequently been detected in the vagina and is found much more commonly in women with BV than in those with normal flora.^{52-55;59;62;72;103;105-107;109;112;113;155-160} In addition to producing lactic acid,^{161;162} some species of *Atopobium* have peptidyl peptidase activity and produce significant amounts of ammonia in other environments¹⁶³⁻¹⁶⁵ where sugars are a scarce source of energy. This may be why *A. vaginae* is found more often in the vagina of postmenopausal women, not on hormone replacement therapy (HRT) compared to those who are taking HRT.¹¹² *Prevotella bivia* (formerly *Bacteroides bivia*) also produces ammonia which is known to act as a substrate to promote the growth of *G. vaginalis*.¹⁶⁶ *A. vaginae* is strictly anaerobic and *in-vitro* is very sensitive to clindamycin¹⁵⁷ but highly resistant to nitro-imidazoles such as metronidazole¹⁵⁷ and secnidazole.¹⁵⁶

High Diversity of flora in BV compared to normal flora

Using various molecular-based techniques and usually Amsel clinical criteria¹⁶⁷ or Nugent score¹¹⁰ to classify normal or abnormal flora, a number of studies have demonstrated a high diversity of organisms in women with BV compared to women with normal flora. Collectively, these studies demonstrate the presence of novel bacterial species previously unidentified using cultivation-dependent techniques.⁵¹⁻⁵⁶ They have also demonstrated that many of these organisms have specificity for BV and that the number of phylotypes found in association with BV is statistically significantly greater than the number detected in the presence of intermediate flora (a distinct entity in its own right)^{168;169} or normal flora.^{49;52-54;56;65;105-107;109;157} This statistic is largely due to the extreme dominance of lactobacilli in healthy women, which makes detection of other species unlikely, even when they are present 100,000 or more cells per sample.

Many of these organisms will be unfamiliar to clinicians (Table 2) though for many of them, there is evidence of disease association. The renamed *Atopobium parvulum*, *Atopobium minutum* and *Atopobium rimae* have been associated with dental abscesses and oral infections,^{151;162;165;170;171} tubo-ovarian abscesses,¹⁷² and abdominal wound infection, supporting the view that these organisms may be pathogenic to the host. *Leptotrichia sanguinegens/amnionii* has been reported in association with post-partum endometritis, adnexal masses and fetal death,¹⁷³⁻¹⁷⁵ and has been detected in the amniotic fluid of women with PTL, PPROM and preeclampsia.¹⁷⁶⁻¹⁷⁸ Also, in a study of 45 women with salpingitis and 44 controls (women seeking tubal ligation), bacterial 16S rRNA sequences were found in the fallopian tube specimens of 24% of cases and in no controls. Bacteria phylotypes closely related to *Leptotrichia* species and *A. vaginae* were among those identified in cases.¹⁷⁹ In addition, *Dialister pneumosintes* was found as the sole agent in blood culture from a woman with suppurative postpartum ovarian thrombosis.¹⁸⁰

In summary, these studies have demonstrated that different subjects with BV have different microbial profiles indicating heterogeneity in the composition of bacterial taxa in women with BV. Women without BV had bacterial communities dominated by *Lactobacillus*

species accounting for 86% of all sequences. In contrast, women with BV did not possess a single dominant phylotype but contained a diverse array of vaginal bacteria, often at relative low abundance.

Molecular-based tools for diagnosis of BV

BV can be diagnosed clinically, or using composite clinical criteria,¹⁶⁷ microscopically,^{110;181-186} enzymatically,¹⁸⁷⁻¹⁹⁰ chromatographically^{191;192} or using qualitative or semi-quantitative culture methods.¹⁹ Currently, the gold standard is Nugent score¹¹⁰ but the number of methods testifies to the fact that no single test is ideal and that they can all provide false positive and false negative results. Findings from molecular-based studies are now highlighting possible explanations for why diagnosis by microscopy may be inconsistent and why molecular methods may replace them.

One of the three organisms quantified as part of the Nugent score is *Mobiluncus*. Several cloning and sequencing studies have identified *Mobiluncus* only rarely.^{53;58;106} Fluorescence in situ hybridization (FISH) technology has demonstrated that BV associated bacterium (BVAB)-1 has a curved rod morphology,⁵³ similar to *Mobiluncus* morphotypes, and it is possible that with microscopic examination of vaginal smears, *Mobiluncus* species may have been overrepresented and mistaken for BVAB-1.^{62;193} Alternatively, since species specific PCR agrees with the Nugent score *Mobiluncus* may be missed in universal PCR studies because it frequently falls below a threshold titre where it can be detected.⁷⁸

Zhou et al (2004) observed that the urea produced by *Atopobium* species was associated with halitosis,¹⁶⁴ and that similar species of *Megasphaera* caused beer spoilage by turbidity, off-flavors and off-colors.^{194;195} They concluded that if two genera associated with malodorous metabolites can be found in the vagina of healthy women, and amines can be found in women without BV, then diagnostic techniques to diagnose BV, based on upon amine production and odor formation^{167;189;192} may need to be amended.⁶²

Microscopically, *Atopobium* species are gram positive, elliptical cocci or rod-shaped organisms that occur, singly, in pairs or short chains. The variable cell morphology of *Atopobium* renders it well camouflaged among the mixture of other species present in bacterial communities where the Nugent score is ≥ 4 . *A. vaginae* is fastidious, grows anaerobically and forms small pin-head colonies on culture that are easily missed.¹⁵⁴ Although phylogenetically different from other lactic acid producing bacteria, they are not phenotypically exceptional and it is not difficult to see why the significance of this organism based on culture, microscopy and phenotype may be overlooked and under-appreciated.

Using species specific primers, the relationship between five fastidious organisms associated with BV, were compared with BV diagnosed by Amsel and/or Nugent scores, and also with the individual clinical criteria of Amsel.¹⁹⁶ The two biovars of *Ureaplasma urealyticum* (*U. parvum* and *U. urealyticum* – biovar 2) were associated with vaginal discharge and raised pH, but not with BV by either Amsel or Nugent criteria or any of the individual Amsel clinical criteria. In contrast, with *Leptotrichia sanguinegens/amnionii*, *A. vaginae* and BVAB-1, elevated pH > 4.5 was a universal feature and they were all associated with BV by both Amsel and Nugent criteria, and with the finding of $>20\%$ of epithelial cells as clue cells, a feature already reported.⁵³ A positive test for amine odor on addition of 10% solution of potassium hydroxide was significantly more likely in women testing positive for BVAB-1. Douching is a recognized risk factor for BV¹⁹⁷ and the detection of *Leptotrichia* and *A. vaginae* was three times more likely and BVAB-1 twice as likely when women reported douching.¹⁹⁶

Fredricks et al, in two linked studies noted that some organisms or combination of organisms had high sensitivities or specificities for the diagnosis of BV using Amsel criteria^{53;72} and Nugent score.⁵³ (Table3). Using quantitative real time PCR, Menard et al firstly examined qualitatively the association of individual organisms with BV diagnosed by Nugent score. To optimize the molecular methods for routine practice, an adjusted quantification was made creating a threshold of DNA copies/mL for lactobacilli and several organisms known to be associated with BV (Table 4). At a threshold of $\geq 10^8$ DNA copies/mL, *Lactobacillus* species was predictive of normal flora (Sensitivity 44%, Specificity 100%). BVAB-1, BVAB-2 and BVAB-3 alone or in combination had high specificity for BV diagnosed by Amsel criteria.

The combination of *A. vaginae* and *G. vaginalis* for the diagnosis of BV

Since *A. vaginae* and *G. vaginalis* are frequently detected in association with BV a number of authors using molecular-based techniques have examined the possibility of combining these two organisms as a means of diagnosing BV.^{52;53;59;112;155;159;160} Using DNA quantitation, 19/20 BV samples had either a DNA level for *A. vaginae* $\geq 10^8$ copies/mL or *G. vaginalis* $\geq 10^9$ copies/mL and 9/20 had both. The combination of an *A. vaginae* DNA level $\geq 10^8$ copies/mL and a *G. vaginalis* DNA level $\geq 10^9$ copies/mL demonstrated the best predictive criteria for the diagnosis of BV with excellent sensitivity (95%) specificity (99%) negative predictive value (NPV) (99%) and positive predictive value (PPV) (95%).¹⁵⁹ When the quality and reproducibility of this combination was applied prospectively for validation of the Nugent score in 56 pregnant women the NPV was 96% and the PPV was 99%.¹⁵⁹

Culture-Independent Techniques to Assess the Treatment of Recurrent, Persistent or Resistant BV

Cure of BV or improvement in symptoms following recommended treatments with metronidazole or clindamycin¹³⁵ reaches 83-94% by seven to 21 days.^{198;199} While the short term treatment response is acceptable, BV persists or recurs in 11-29% of women at one month,^{198;200;201} 30% of patients relapse within three months and recurrence rates may be more than 50% within a year.^{155;202-204} Only 48% of women will be colonized by H₂O₂ producing *Lactobacilli* 70-90 days after treatment with either clindamycin or metronidazole.^{201;205}

A number of molecular-based studies^{53;105;155;206;207} have addressed the problems of recurrent or persistent BV over time, and why some women with BV may be resistant to cure. A consistent finding in these studies as women lapse in and out of being BV positive and BV negative is the stability of vaginal flora requiring few phylotypes and *Lactobacillus* dominance with *L. crispatus* and/or *L. jensenii* in women who remain or become BV negative. In contrast, those who become BV positive are commonly colonized by *L. iners* with many other non-*Lactobacillus* species present.^{53;105} Three studies have addressed the problem of persistent or recurrent BV using culture-independent techniques.^{155;206;207} Women with BV were appropriately treated and followed up in a large, prospective, cross-sectional cohort study over a 12 month period. *A. vaginae* was detected in 75% and *G. vaginalis* in 100% of women with recurrent BV. Women in whom both organisms were detected had higher rates of recurrence of BV (83%) compared to women with *G. vaginalis* alone (38%) (p<0.001). Of relevance is the fact that >90% of a biofilm identified on vaginal epithelial cells of women with BV was composed of *A. vaginae* and *G. vaginalis*.^{208;209} The biofilm may have interfered with treatment, but the authors were unable to determine whether recurrence was due to inadequate treatment and undetectably low levels of residual organisms after treatment (i.e. relapse), or re-infection from sexual partners, which they thought was feasible, or disruption of normal flora from other exogenous factors.¹⁵⁵

In an isolated study, several bacterial species were detected, none of which are commonly associated with BV. Organisms normally associated with BV were not detected. This atypical form of BV might explain why conventional therapy did not work and may indicate that other anti-microbial therapies may have been more effective.²⁰⁶ Finally, using species specific 16S rDNA PCR assays targeting 17 different BV associated bacteria in 131 women with BV, the vaginal microbiome was sampled pre-treatment and one month after for test of cure. Treatment was with a five day course of intravaginal metronidazole gel. At one month after treatment, BV was still present in 26% of women. The baseline detection of BVAB -1, BVAB -2, and BVAB -3, *Peptoniphilus lacrimalis* or *Megasphaera* phylotype was significantly associated with persistence of BV at test of cure. The authors concluded that pretreatment vaginal microbiology at diagnosis might define the risk of antibiotic failure.²⁰⁷ We anticipate that these correlations will become clearer and more meaningful when studies are repeated with quantitative PCR instead of simply using detection / incidence.

Culture-independent studies in pregnancy

Culture independent techniques have been used to measure prevalence, diversity and abundance of organisms particularly ureaplasmas²¹⁰ in amniotic fluid in association with suspected cervical insufficiency,²¹¹ preterm labor,^{176;212} PPRM,^{178;213} babies small for gestational age,²¹⁴ preeclampsia¹⁷⁷ and the potential for bacteria from the oral cavity to colonize amniotic fluid.²¹⁵ However, apart from combining pregnant women with non-pregnant women to swell sample numbers,^{52;160} the information with respect to the vaginal microbiome in pregnant women is limited particularly with respect to the outcome of pregnancy, especially preterm birth.

Using species specific primers, Wilks et al,¹⁰¹ quantified the production of H₂O₂ by lactobacilli from swabs taken at 20 weeks gestation from the vagina of 73 women considered to be at high risk of preterm birth according to the Creasy criteria.²¹⁶ The amounts of H₂O₂ production varied between species of *Lactobacillus*. The presence of lactobacilli producing high levels of H₂O₂ was associated with a reduced incidence of BV at 20 weeks gestation and subsequent chorioamnionitis. The authors postulated that H₂O₂-producing lactobacilli reduced the incidence of ascending genital tract colonization in pregnancy which leads to infection and preterm birth.¹⁰¹ Unfortunately the role of *L. iners*, was not tested, because MRS agar culture medium was used in the study.⁹⁰

In pregnant Japanese women, Tamrakar et al¹¹⁶ largely confirmed the findings of Fredricks et al 2005⁵³ in non-pregnant women. The prevalence of *L. crispatus*, *L. jensenii*, and *L. gasseri* was significantly higher, while that of BVAB-2, *Megasphaera*, *Leptotrichia* and *Eggerthella*-like bacterium were significantly lower in women with a normal Nugent score, compared to those with BV. The prevalence of *L. iners* did not differ between the these groups, and women with *L. iners* were more likely to be colonized by BVAB-2, *Megasphaera*, *Leptotrichia* and *Eggerthella*-like bacterium.¹¹⁶

In a longitudinal study of 100 pregnant women, vaginal swabs were obtained at mean gestational ages of 8.6, 21.2, and 32.4 weeks respectively.²¹⁷ In first trimester, 77 women had normal or *Lactobacillus* dominated flora, 13 of whom developed abnormal flora in the second or third trimester. When first trimester normal flora was dominated by *L. gasseri* or *L. iners* there was a 10-fold risk of conversion to abnormal flora. In contrast, normal flora comprising *L. crispatus* had a five-fold decreased risk of conversion to abnormal flora.²¹⁷ This may be because *L. gasseri* and *L. iners* only produce H₂O₂ in a small percentage of strains.^{95;131}

CONCLUSIONS

Molecular based techniques provide important new information about vaginal microbial flora and permit identification of previously under-detected and hence under-appreciated organisms such as *L. iners* and *A. vaginae*. Molecular based techniques are not without their problems, and will not replace culture based techniques, but, when used in combination, add greatly to our understanding of vaginal flora. In the majority of circumstances, normal vaginal flora is dominated by *Lactobacillus* species. In the absence of lactobacilli, normality can be maintained by other, more fastidious lactic acid producing bacteria. In keeping with the theories of “competitive exclusion” and “bacterial interference”, when lactobacilli dominate the vaginal flora, culture-independent techniques have demonstrated that the healthy vagina is usually colonized by only one or two dominant *Lactobacillus* species, mainly from *L. crispatus*, *L. iners*, *L. jensenii* and *L. gasseri*. The dominant *Lactobacillus* species may differ racially or geographically, but the principle of numerical dominance persists, and may be an important defense mechanism. Without molecular based techniques, phenotypic identification of lactobacilli is difficult and so is normally only carried out to the genus level. By being able to identify lactobacilli to the species level, we should be better able to understand the role of different species of *Lactobacillus*, particularly with respect to their ability to produce H₂O₂ and to function as a probiotic.

Molecular-based techniques indicate that there is a far greater diversity of microorganisms associated with BV than has been evident from cultivation-dependant techniques. These diverse organisms accumulate to form different communities or profiles which make it likely that BV is not a single entity, but a syndrome of variable composition which cause a variety of symptoms, different phenotypical outcomes, and may result in variable responses to different antibiotic regimens. Some organisms or combinations of organisms have a high specificity for BV such that in future using molecular quantification, we may better diagnose each sub-type of BV and tailor treatment appropriately. The information with respect to the vaginal microbiome in pregnant women is limited particularly with respect to preterm birth. This gap is striking, given the importance of preterm birth problem worldwide, and must become a research and funding priority. By better understanding the vaginal microbiome during pregnancy, we may be able to predict and prevent some of the great obstetric syndromes like PPROM, preterm labor and preterm birth which is associated with infection and significant infant mortality and morbidity. This better understanding is imminent, with the onset of studies using much more powerful sequencing technologies.

Acknowledgments

Supported (in part) by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS.

Reference List

1. Witkin SS, Linhares IM, Giraldo P. Bacterial flora of the female genital tract: function and immune regulation 3. *Best Pract Res Clin Obstet Gynaecol* 2007;21(3):347–354. [PubMed: 17215167]
2. Plitt SS, Garfein RS, Gaydos CA, Strathdee SA, Sherman SG, Taha TE. Prevalence and correlates of chlamydia trachomatis, neisseria gonorrhoeae, trichomonas vaginalis infections, and bacterial vaginosis among a cohort of young injection drug users in Baltimore, Maryland. *Sex Transm Dis* 2005;32(7):446–453. [PubMed: 15976603]
3. Schwebke JR. Gynecologic consequences of bacterial vaginosis. *Obstet Gynecol Clin North Am* 2003;30(4):685–694. [PubMed: 14719845]
4. Soper DE, Bump RC, Hurt WG. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. *Am J Obstet Gynecol* 1990;163(3):1016–1021. [PubMed: 2403128]

5. Cohen CR, Duerr A, Pruithithada N, Ruggao S, Hillier S, Garcia P, et al. Bacterial vaginosis and HIV seroprevalence among female commercial sex workers in Chiang Mai, Thailand. *AIDS* 1995;9(9):1093–1097. [PubMed: 8527084]
6. Cu-Uvin S, Hogan JW, Warren D, Klein RS, Peipert J, Schuman P, et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. *Clin Infect Dis* 1999;29(5):1145–1150. [PubMed: 10524955]
7. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. *J Infect Dis* 1999;180(6):1863–1868. [PubMed: 10558942]
8. Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. *Lancet* 1997;350(9077):546–550. [PubMed: 9284776]
9. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. *AIDS* 1998;12(13):1699–1706. [PubMed: 9764791]
10. Larsson PG, Platz-Christensen JJ, Dalaker K, Eriksson K, Fahraeus L, Irminger K, et al. Treatment with 2% clindamycin vaginal cream prior to first trimester surgical abortion to reduce signs of postoperative infection: a prospective, double-blinded, placebo-controlled, multicenter study. *Acta Obstet Gynecol Scand* 2000;79(5):390–396. [PubMed: 10830767]
11. Ralph SG, Rutherford AJ, Wilson JD. Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study. *BMJ* 1999;319(7204):220–223. [PubMed: 10417083]
12. Llahi-Camp JM, Rai R, Ison C, Regan L, Taylor-Robinson D. Association of bacterial vaginosis with a history of second trimester miscarriage. *Hum Reprod* 1996;11(7):1575–1578. [PubMed: 8671507]
13. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage 665. *BMJ* 1994;308(6924):295–298. [PubMed: 8124116]
14. Azarگون A, Darvishzadeh S. Association of bacterial vaginosis, trichomonas vaginalis, and vaginal acidity with outcome of pregnancy 1. *Arch Iran Med* 2006;9(3):213–217. [PubMed: 16859053]
15. Eschenbach DA, Gravett MG, Chen KC, Hoyme UB, Holmes KK. Bacterial vaginosis during pregnancy. An association with prematurity and postpartum complications 1973. *Scand J Urol Nephrol Suppl* 1984;86:213–222. [PubMed: 6336136]
16. Gratacos E, Figueras F, Barranco M, Vila J, Cararach V, Alonso PL, et al. Spontaneous recovery of bacterial vaginosis during pregnancy is not associated with an improved perinatal outcome 1971. *Acta Obstet Gynecol Scand* 1998;77(1):37–40. [PubMed: 9492715]
17. Gravett MG, Nelson HP, DeRouen T, Critchlow C, Eschenbach DA, Holmes KK. Independent associations of bacterial vaginosis and Chlamydia trachomatis infection with adverse pregnancy outcome 1969. *JAMA* 1986;256(14):1899–1903. [PubMed: 3761496]
18. Holst E, Goffeng AR, Andersch B. Bacterial vaginosis and vaginal microorganisms in idiopathic premature labor and association with pregnancy outcome 1972. *J Clin Microbiol* 1994;32(1):176–186. [PubMed: 8126176]
19. McDonald HM, O'Loughlin JA, Jolley P, Vigneswaran R, McDonald PJ. Prenatal microbiological risk factors associated with preterm birth. *Br J Obstet Gynaecol* 1992;99(3):190–196. [PubMed: 1606115]
20. Wennerholm UB, Holm B, Mattsby-Baltzer I, Nielsen T, Platz-Christensen J, Sundell G, et al. Fetal fibronectin, endotoxin, bacterial vaginosis and cervical length as predictors of preterm birth and neonatal morbidity in twin pregnancies 1970. *Br J Obstet Gynaecol* 1997;104(12):1398–1404. [PubMed: 9422019]
21. Lamont, RF. Bacterial Vaginosis. In: Critchley, H.; Bennett, P.; Thornton, S., editors. *Preterm Birth*. London: RCOG Press; 2004. p. 163-180.

22. McGregor JA, French JI, Jones W, Milligan K, McKinney PJ, Patterson E, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream 1966. *Am J Obstet Gynecol* 1994;170(4):1048–1059. [PubMed: 8166188]
23. Kurki T, Sivonen A, Renkonen OV, Savia E, Ylikorkala O. Bacterial vaginosis in early pregnancy and pregnancy outcome. *Obstet Gynecol* 1992;80(2):173–177. [PubMed: 1635726]
24. Riduan JM, Hillier SL, Utomo B, Wiknjostastro G, Linnan M, Kandun N. Bacterial vaginosis and prematurity in Indonesia: association in early and late pregnancy. *Am J Obstet Gynecol* 1993;169(1):175–178. [PubMed: 8333449]
25. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. *N Engl J Med* 1995;333(26):1737–1742. [PubMed: 7491137]
26. Meis PJ, Goldenberg RL, Mercer B, Moawad A, Das A, McNellis D, et al. The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *Am J Obstet Gynecol* 1995;173(4):1231–1235. [PubMed: 7485327]
27. Gibbs RS. Chorioamnionitis and bacterial vaginosis 7. *Am J Obstet Gynecol* 1993;169(2 Pt 2):460–462. [PubMed: 8357045]
28. Martius J, Eschenbach DA. The role of bacterial vaginosis as a cause of amniotic fluid infection, chorioamnionitis and prematurity--a review 8. *Arch Gynecol Obstet* 1990;247(1):1–13. [PubMed: 2178562]
29. Jacobsson B, Pernevi P, Chidekel L, Jorgen Platz-Christensen J. Bacterial vaginosis in early pregnancy may predispose for preterm birth and postpartum endometritis 5. *Acta Obstet Gynecol Scand* 2002;81(11):1006–1010. [PubMed: 12421167]
30. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis. *Obstet Gynecol* 1990;75(1):52–58. [PubMed: 2296423]
31. Romero, R.; Espinoza, J.; Mazor, M.; Chaiworapongsa, T. The preterm parturition syndrome. In: Critchley, H.; Bennett, P.; Thornton, S., editors. *Preterm Birth*. London: RCOG Press; 2004. p. 28–60.
32. Gotsch F, Romero R, Kusanovic JP, Mazaki-Tovi S, Pineles BL, Erez O, et al. The fetal inflammatory response syndrome. *Clin Obstet Gynecol* 2007;50(3):652–683. [PubMed: 17762416]
33. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. *Am J Obstet Gynecol* 1998;179(1):194–202. [PubMed: 9704787]
34. Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. *Pediatrics* 2000;106(4):659–671. [PubMed: 11015506]
35. Fellman V, Hellstrom-Westas L, Norman M, Westgren M, Kallen K, Lagercrantz H, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. *JAMA* 2009;301(21):2225–2233. [PubMed: 19491184]
36. March of Dimes Foundation. *March of Dimes White Paper on Preterm Birth: the Global and Regional Toll*. Internet. Dec 16;2009
37. Petrou S, Abangma G, Johnson S, Wolke D, Marlow N. Costs and Health Utilities Associated with Extremely Preterm Birth: Evidence from the EPICure Study. *Value Health*. 2009
38. Institute of Medicine. *Preterm Birth: Causes, Consequences, and Prevention*. Institute of Medicine of the National Academies. 2006. Dec 16;2009
39. Keirse MJ. New perspectives for the effective treatment of preterm labor 10. *Am J Obstet Gynecol* 1995;173(2):618–628. [PubMed: 7645643]
40. Chow AW, Bartlett KH. Sequential assessment of vaginal microflora in healthy women randomly assigned to tampon or napkin use. *Rev Infect Dis* 1989;11(Suppl 1):S68–S73. [PubMed: 2928654]
41. Johnson SR, Petzold CR, Galask RP. Qualitative and quantitative changes of the vaginal microbial flora during the menstrual cycle. *Am J Reprod Immunol Microbiol* 1985;9(1):1–5. [PubMed: 4051082]

42. Larsen B, Monif GR. Understanding the bacterial flora of the female genital tract. *Clin Infect Dis* 2001;32(4):e69–e77. [PubMed: 11181139]
43. Marrazzo JM, Koutsky LA, Eschenbach DA, Agnew K, Stine K, Hillier SL. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. *J Infect Dis* 2002;185(9):1307–1313. [PubMed: 12001048]
44. Stahl, CE.; Hill, GB. The clinical perspectives in obstetrics and gynecology. In: Galask, RP., editor. *Infectious Diseases in the Female Patient*. New York: Springer; 2009. p. 16-42.
45. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. *Science* 2006;312(5778):1355–1359. [PubMed: 16741115]
46. Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of *Oxalobacter formigenes*. *J Urol* 2001;166(4):1487–1491. [PubMed: 11547118]
47. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. *Nature* 2007;449(7164):804–810. [PubMed: 17943116]
48. Van HJ, Green DB. Relationship between the concentration of bacteria in saliva and the colonization of teeth in humans. *Infect Immun* 1974;9(4):624–630. [PubMed: 4822863]
49. Kim TK, Thomas SM, Ho M, Sharma S, Reich CI, Frank JA, et al. Heterogeneity of vaginal microbial communities within individuals. *J Clin Microbiol* 2009;47(4):1181–1189. [PubMed: 19158255]
50. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. *Science* 2005;308(5728):1635–1638. [PubMed: 15831718]
51. Pavlova SI, Kilic AO, Kilic SS, So JS, Nader-Macias ME, Simoes JA, et al. Genetic diversity of vaginal lactobacilli from women in different countries based on 16S rRNA gene sequences. *J Appl Microbiol* 2002;92(3):451–459. [PubMed: 11872120]
52. Verhelst R, Verstraelen H, Claeys G, Verschraegen G, Delanghe J, Van SL, et al. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between *Atopobium vaginae*, *Gardnerella vaginalis* and bacterial vaginosis. *BMC Microbiol* 2004;4:16. [PubMed: 15102329]
53. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med* 2005;353(18):1899–1911. [PubMed: 16267321]
54. Oakley BB, Fiedler TL, Marrazzo JM, Fredricks DN. Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. *Appl Environ Microbiol* 2008;74(15):4898–4909. [PubMed: 18487399]
55. Yamamoto T, Zhou X, Williams CJ, Hochwalt A, Forney LJ. Bacterial populations in the vaginas of healthy adolescent women. *J Pediatr Adolesc Gynecol* 2009;22(1):11–18. [PubMed: 19232297]
56. Zozaya-Hinchliffe M, Martin DH, Ferris MJ. Prevalence and abundance of uncultivated *Megasphaera*-like bacteria in the human vaginal environment. *Appl Environ Microbiol* 2008;74(5):1656–1659. [PubMed: 18203860]
57. Hill JE, Goh SH, Money DM, Doyle M, Li A, Crosby WL, et al. Characterization of vaginal microflora of healthy, nonpregnant women by chaperonin-60 sequence-based methods. *Am J Obstet Gynecol* 2005;193(3 Pt 1):682–692. [PubMed: 16150261]
58. Hyman RW, Fukushima M, Diamond L, Kumm J, Giudice LC, Davis RW. Microbes on the human vaginal epithelium. *Proc Natl Acad Sci U S A* 2005;102(22):7952–7957. [PubMed: 15911771]
59. Trama JP, Pascal KE, Zimmerman J, Self MJ, Mordechai E, Adelson ME. Rapid detection of *Atopobium vaginae* and association with organisms implicated in bacterial vaginosis. *Mol Cell Probes* 2008;22(2):96–102. [PubMed: 17913456]
60. Schellenberg J, Links MG, Hill JE, Dumonceaux TJ, Peters GA, Tyler S, et al. Pyrosequencing of the chaperonin-60 universal target as a tool for determining microbial community composition. *Appl Environ Microbiol* 2009;75(9):2889–2898. [PubMed: 19270139]
61. Yachi S, Loreau M. Biodiversity and ecosystem productivity in a fluctuating environment: the insurance hypothesis. *Proc Natl Acad Sci U S A* 1999;96(4):1463–1468. [PubMed: 9990046]
62. Zhou X, Bent SJ, Schneider MG, Davis CC, Islam MR, Forney LJ. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. *Microbiology* 2004;150(Pt 8):2565–2573. [PubMed: 15289553]

63. Dethlefsen L, Fall-Ngai M, Relman DA. An ecological and evolutionary perspective on human-microbe mutualism and disease. *Nature* 2007;449(7164):811–818. [PubMed: 17943117]
64. Haruta S, Kato S, Yamamoto K, Igarashi Y. Intertwined interspecies relationships: approaches to untangle the microbial network. *Environ Microbiol.* 2009
65. Burton JP, Reid G. Evaluation of the bacterial vaginal flora of 20 postmenopausal women by direct (Nugent score) and molecular (polymerase chain reaction and denaturing gradient gel electrophoresis) techniques. *J Infect Dis* 2002;186(12):1770–1780. [PubMed: 12447763]
66. Hugenholtz P, Pace NR. Identifying microbial diversity in the natural environment: a molecular phylogenetic approach. *Trends Biotechnol* 1996;14(6):190–197. [PubMed: 8663938]
67. Pace NR. A molecular view of microbial diversity and the biosphere. *Science* 1997;276(5313):734–740. [PubMed: 9115194]
68. Hugenholtz P, Goebel BM, Pace NR. Impact of culture-independent studies on the emerging phylogenetic view of bacterial diversity. *J Bacteriol* 1998;180(18):4765–4774. [PubMed: 9733676]
69. Baker GC, Smith JJ, Cowan DA. Review and re-analysis of domain-specific 16S primers. *J Microbiol Methods* 2003;55(3):541–555. [PubMed: 14607398]
70. Schmidt TM. The maturing of microbial ecology. *Int Microbiol* 2006;9(3):217–223. [PubMed: 17061212]
71. Weng L, Rubin EM, Bristow J. Application of sequence-based methods in human microbial ecology. *Genome Res* 2006;16(3):316–322. [PubMed: 16461883]
72. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. *J Clin Microbiol* 2007;45(10):3270–3276. [PubMed: 17687006]
73. Hillier SL. The complexity of microbial diversity in bacterial vaginosis. *N Engl J Med* 2005;353(18):1886–1887. [PubMed: 16267319]
74. Donachie SP, Foster JS, Brown MV. Culture clash: challenging the dogma of microbial diversity. *ISME J* 2007;1(2):97–99. [PubMed: 18043618]
75. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, et al. Genome sequencing in microfabricated high-density picolitre reactors. *Nature* 2005;437(7057):376–380. [PubMed: 16056220]
76. Petrosino JF, Highlander S, Luna RA, Gibbs RA, Versalovic J. Metagenomic pyrosequencing and microbial identification. *Clin Chem* 2009;55(5):856–866. [PubMed: 19264858]
77. Forney LJ, Zhou X, Brown CJ. Molecular microbial ecology: land of the one-eyed king. *Curr Opin Microbiol* 2004;7(3):210–220. [PubMed: 15196487]
78. Kalra A, Palcu CT, Sobel JD, Akins RA. Bacterial Vaginosis: Culture- and PCR-based Characterizations of a Complex Polymicrobial Disease's Pathobiology. *Curr Infect Dis Rep* 2007;9(6):485–500. [PubMed: 17999885]
79. Srinivasan S, Fredricks DN. The human vaginal bacterial biota and bacterial vaginosis. *Interdiscip Perspect Infect Dis* 2008;2008:750479. [PubMed: 19282975]
80. Skarin A, Sylwan J. Vaginal lactobacilli inhibiting growth of *Gardnerella vaginalis*, *Mobiluncus* and other bacterial species cultured from vaginal content of women with bacterial vaginosis. *Acta Pathol Microbiol Immunol Scand B* 1986;94(6):399–403. [PubMed: 3494379]
81. Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutsky LA, Wolner-Hanssen P, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. *J Infect Dis* 1996;174(5):1058–1063. [PubMed: 8896509]
82. Aroutcheva AA, Simoes JA, Faro S. Antimicrobial protein produced by vaginal *Lactobacillus acidophilus* that inhibits *Gardnerella vaginalis*. *Infect Dis Obstet Gynecol* 2001;9(1):33–39. [PubMed: 11368257]
83. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. *Inflamm Bowel Dis* 2009;15(2):300–310. [PubMed: 18626975]
84. Doderlein A. Das scheidensekret und seine bedeutung fur puerperalfieber. *Zbl Bakteriol* 1892;11:699.
85. Thomas S. Doderlein's Bacillus: *Lactobacillus Acidophilus*. *J Infect Dis* 1928;43:218–227.

86. Lauer E, Helming C, Kandler O. Heterogeneity of the species *Lactobacillus acidophilus* (Moro) Hansen and Mocquot as revealed by biochemical characteristics and DNA-DNA hybridization. *Zentbl Bakteriol Microbiol Hyg Abt* 1980;1:150–168.
87. Johnson JL, PHELPS CF, CUMMINS CS, LONDON J, GASSER F. Taxonomy of the *Lactobacillus acidophilus* Group. *Int J Syst Bacteriol* 1980;30(1):53–68.
88. Schleifer KH, Ludwig W. Phylogeny of the genus *Lactobacillus* and related genera. *Syst Appl Microbiol* 1995;18:461–467.
89. Du Plessis EM, Dicks LM. Evaluation of random amplified polymorphic DNA (RAPD)-PCR as a method to differentiate *Lactobacillus acidophilus*, *Lactobacillus crispatus*, *Lactobacillus amylovorus*, *Lactobacillus gallinarum*, *Lactobacillus gasseri*, and *Lactobacillus johnsonii*. *Curr Microbiol* 1995;31(2):114–118. [PubMed: 7606186]
90. Falsen E, Pascual C, Sjoden B, Ohlen M, Collins MD. Phenotypic and phylogenetic characterization of a novel *Lactobacillus* species from human sources: description of *Lactobacillus iners* sp. nov. *Int J Syst Bacteriol* 1999;49(Pt 1):217–221. [PubMed: 10028266]
91. Klein G, Pack A, Bonaparte C, Reuter G. Taxonomy and physiology of probiotic lactic acid bacteria. *Int J Food Microbiol* 1998;41(2):103–125. [PubMed: 9704860]
92. Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. *Rev Infect Dis* 1990;12(5):856–872. [PubMed: 2237129]
93. Zhong W, Millsap H, Bialkowska-Hobrzanska H, Reid G. Differentiation of *Lactobacillus* species by molecular typing. *Appl Environ Microbiol* 1998;64:2418–2423. [PubMed: 9647809]
94. Dimitonova SP, Bakalov BV, eksandrova-Georgieva RN, Danova ST. Phenotypic and molecular identification of lactobacilli isolated from vaginal secretions. *J Microbiol Immunol Infect* 2008;41(6):469–477. [PubMed: 19255690]
95. Antonio MA, Hawes SE, Hillier SL. The identification of vaginal *Lactobacillus* species and the demographic and microbiologic characteristics of women colonized by these species. *J Infect Dis* 1999;180(6):1950–1956. [PubMed: 10558952]
96. Reid G, McGroarty JA, Tomczek L, Bruce AW. Identification and plasmid profiles of *Lactobacillus* species from the vagina of 100 healthy women. *FEMS Immunol Med Microbiol* 1996;15(1):23–26. [PubMed: 8871112]
97. Vasquez A, Jakobsson T, Ahrne S, Forsum U, Molin G. Vaginal lactobacillus flora of healthy Swedish women. *J Clin Microbiol* 2002;40(8):2746–2749. [PubMed: 12149323]
98. Tarnberg M, Jakobsson T, Jonasson J, Forsum U. Identification of randomly selected colonies of lactobacilli from normal vaginal fluid by pyrosequencing of the 16S rDNA variable V1 and V3 regions. *APMIS* 2002;110(11):802–810. [PubMed: 12588421]
99. Giorgi A, Torriani S, Dellaglio F, Bo G, Stola E, Bernuzzi L. Identification of vaginal lactobacilli from asymptomatic women. *Microbiologica* 1987;10(4):377–384. [PubMed: 3695985]
100. Song YL, Kato N, Matsumiya Y, Liu CX, Kato H, Watanabe K. Identification of and hydrogen peroxide production by fecal and vaginal lactobacilli isolated from Japanese women and newborn infants. *J Clin Microbiol* 1999;37(9):3062–3064. [PubMed: 10449509]
101. Wilks M, Wiggins R, Whiley A, Hennessy E, Warwick S, Porter H, et al. Identification and H₂O₂ production of vaginal lactobacilli from pregnant women at high risk of preterm birth and relation with outcome. *J Clin Microbiol* 2004;42(2):713–717. [PubMed: 14766841]
102. Anukam KC, Osazuwa EO, Ahonkhai I, Reid G. *Lactobacillus* vaginal microbiota of women attending a reproductive health care service in Benin city, Nigeria. *Sex Transm Dis* 2006;33(1):59–62. [PubMed: 16385223]
103. Zhou X, Brown CJ, Abdo Z, Davis CC, Hansmann MA, Joyce P, et al. Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women. *ISME J* 2007;1(2):121–133. [PubMed: 18043622]
104. Burton JP, Cadieux PA, Reid G. Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation. *Appl Environ Microbiol* 2003;69(1):97–101. [PubMed: 12513982]

105. Wertz J, Isaacs-Cosgrove N, Holzman C, Marsh TL. Temporal Shifts in Microbial Communities in Nonpregnant African-American Women with and without Bacterial Vaginosis. *Interdiscip Perspect Infect Dis* 2008;2008:181253. [PubMed: 19277101]
106. Thies FL, Konig W, Konig B. Rapid characterization of the normal and disturbed vaginal microbiota by application of 16S rRNA gene terminal RFLP fingerprinting. *J Med Microbiol* 2007;56(Pt 6):755–761. [PubMed: 17510259]
107. Biagi E, Vitali B, Pugliese C, Candela M, Donders GG, Brigidi P. Quantitative variations in the vaginal bacterial population associated with asymptomatic infections: a real-time polymerase chain reaction study. *Eur J Clin Microbiol Infect Dis* 2009;28(3):281–285. [PubMed: 18762999]
108. Shi Y, Chen L, Tong J, Xu C. Preliminary characterization of vaginal microbiota in healthy Chinese women using cultivation-independent methods. *J Obstet Gynaecol Res* 2009;35(3):525–532. [PubMed: 19527394]
109. Vitali B, Pugliese C, Biagi E, Candela M, Turrone S, Bellen G, et al. Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. *Appl Environ Microbiol* 2007;73(18):5731–5741. [PubMed: 17644631]
110. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. *J Clin Microbiol* 1991;29(2):297–301. [PubMed: 1706728]
111. Morse, SA.; Butel, JS. Jawetz, Melnick & Adelberg's Medical Microbiology. 23. New York: McGraw Hill; 1995.
112. Burton JP, Devillard E, Cadieux PA, Hammond JA, Reid G. Detection of *Atopobium vaginae* in postmenopausal women by cultivation-independent methods warrants further investigation. *J Clin Microbiol* 2004;42(4):1829–1831. [PubMed: 15071062]
113. Martinez RC, Franceschini SA, Patta MC, Quintana SM, Nunes AC, Moreira JL, et al. Analysis of vaginal lactobacilli from healthy and infected Brazilian women. *Appl Environ Microbiol* 2008;74(14):4539–4542. [PubMed: 18502927]
114. Coolen MJ, Post E, Davis CC, Forney LJ. Characterization of microbial communities found in the human vagina by analysis of terminal restriction fragment length polymorphisms of 16S rRNA genes. *Appl Environ Microbiol* 2005;71(12):8729–8737. [PubMed: 16332868]
115. Garg KB, Ganguli I, Das R, Talwar GP. Spectrum of *Lactobacillus* species present in healthy vagina of Indian women. *Indian J Med Res* 2009;129(6):652–657. [PubMed: 19692744]
116. Tamrakar R, Yamada T, Furuta I, Cho K, Morikawa M, Yamada H, et al. Association between *Lactobacillus* species and bacterial vaginosis-related bacteria, and bacterial vaginosis scores in pregnant Japanese women. *BMC Infect Dis* 2007;7:128. [PubMed: 17986357]
117. Anukam KC, Reid G. Organisms associated with bacterial vaginosis in Nigerian women as determined by PCR-DGGE and 16S rRNA gene sequence. *Afr Health Sci* 2007;7(2):68–72. [PubMed: 17594282]
118. Kilic AO, Pavlova SI, Alpay S, Kilic SS, Tao L. Comparative study of vaginal *Lactobacillus* phages isolated from women in the United States and Turkey: prevalence, morphology, host range, and DNA homology. *Clin Diagn Lab Immunol* 2001;8(1):31–39. [PubMed: 11139192]
119. Ahrne S, Nobaek S, Jeppsson B, Adlerberth I, Wold AE, Molin G. The normal *Lactobacillus* flora of healthy human rectal and oral mucosa. *J Appl Microbiol* 1998;85(1):88–94. [PubMed: 9721659]
120. Benno Y, Endo K, Mizutani T, Namba Y, Komori T, Mitsuoka T. Comparison of fecal microflora of elderly persons in rural and urban areas of Japan. *Appl Environ Microbiol* 1989;55(5):1100–1105. [PubMed: 2547333]
121. Cooperstock, MS.; Zedd, AJ. Intestinal flora of infants. In: Hentges, DJ., editor. *Human intestinal microflora in health and disease*. New York: Academic Press; 1983. p. 79-99.
122. Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, et al. Prevalence of hydrogen peroxide-producing *Lactobacillus* species in normal women and women with bacterial vaginosis. *J Clin Microbiol* 1989;27(2):251–256. [PubMed: 2915019]
123. Marrazzo JM, Antonio M, Agnew K, Hillier SL. Distribution of genital *Lactobacillus* strains shared by female sex partners. *J Infect Dis* 2009;199(5):680–683. [PubMed: 19199538]

124. Chernes TL, Hillier SL, Meyn LA, Busch JL, Krohn MA. A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. *Sex Transm Dis* 2008;35(1):78–83. [PubMed: 17989585]
125. McGroarty JA, Tomeczek L, Pond DG, Reid G, Bruce AW. Hydrogen peroxide production by *Lactobacillus* species: correlation with susceptibility to the spermicidal compound nonoxynol-9. *J Infect Dis* 1992;165(6):1142–1144. [PubMed: 1316413]
126. Nagy E, Petterson M, Mardh PA. Antibiosis between bacteria isolated from the vagina of women with and without signs of bacterial vaginosis. *APMIS* 1991;99(8):739–744. [PubMed: 1859646]
127. Srinivasan S, Liu C, Mitchell CM, Fiedler TL, Thomas KK, Agnew KJ, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. *PLoS One* 2010;5(4):e10197. [PubMed: 20419168]
128. Gardiner GE, Heinemann C, Bruce AW, Beuerman D, Reid G. Persistence of *Lactobacillus fermentum* RC-14 and *Lactobacillus rhamnosus* GR-1 but not *L. rhamnosus* GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. *Clin Diagn Lab Immunol* 2002;9(1):92–96. [PubMed: 11777835]
129. Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R, et al. Oral use of *Lactobacillus rhamnosus* GR-1 and *L. fermentum* RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. *FEMS Immunol Med Microbiol* 2003;35(2):131–134. [PubMed: 12628548]
130. Vallor AC, Antonio MA, Hawes SE, Hillier SL. Factors associated with acquisition of, or persistent colonization by, vaginal lactobacilli: role of hydrogen peroxide production. *J Infect Dis* 2001;184(11):1431–1436. [PubMed: 11709785]
131. Antonio MA, Rabe LK, Hillier SL. Colonization of the rectum by *Lactobacillus* species and decreased risk of bacterial vaginosis. *J Infect Dis* 2005;192(3):394–398. [PubMed: 15995952]
132. Antonio MA, Hillier SL. DNA fingerprinting of *Lactobacillus crispatus* strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. *J Clin Microbiol* 2003;41(5):1881–1887. [PubMed: 12734221]
133. Antonio MA, Meyn LA, Murray PJ, Busse B, Hillier SL. Vaginal colonization by probiotic *Lactobacillus crispatus* CTV-05 is decreased by sexual activity and endogenous *Lactobacilli*. *J Infect Dis* 2009;199(10):1506–1513. [PubMed: 19331578]
134. Smith, T. Parasitism and Disease. Princeton: Princeton University Press; 1934.
135. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recomm Rep* 2006;55(RR-11):1–94. [PubMed: 16888612]
136. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. *BMJ* 1994;308(6924):295–298. [PubMed: 8124116]
137. Oleen-Burkey MA, Hillier SL. Pregnancy complications associated with bacterial vaginosis and their estimated costs. *Infect Dis Obstet Gynecol* 1995;3(4):149–157. [PubMed: 18476039]
138. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. *N Engl J Med* 1995;333(26):1737–1742. [PubMed: 7491137]
139. Hillier SL. The vaginal microbial ecosystem and resistance to HIV. *AIDS Res Hum Retroviruses* 1998;14(Suppl 1):S17–S21. [PubMed: 9581879]
140. Schwebke JR. Role of Vaginal Flora As a Barrier to HIV Acquisition. *Curr Infect Dis Rep* 2001;3(2):152–155. [PubMed: 11286657]
141. Coleman JS, Hitti J, Bukusi EA, Mwachari C, Muliro A, Nguti R, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. *AIDS* 2007;21(6):755–759. [PubMed: 17413697]
142. Sha BE, Zariffard MR, Wang QJ, Chen HY, Bremer J, Cohen MH, et al. Female genital-tract HIV load correlates inversely with *Lactobacillus* species but positively with bacterial vaginosis and *Mycoplasma hominis*. *J Infect Dis* 2005;191(1):25–32. [PubMed: 15592999]

143. Cherpes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. *Clin Infect Dis* 2003;37(3):319–325. [PubMed: 12884154]
144. Kaul R, Nagelkerke NJ, Kimani J, Ngugi E, Bwayo JJ, Macdonald KS, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. *J Infect Dis* 2007;196(11):1692–1697. [PubMed: 18008255]
145. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* infection. *Clin Infect Dis* 2003;36(5):663–668. [PubMed: 12594649]
146. Spear GT, Sikaroodi M, Zariffard MR, Landay AL, French AL, Gillevet PM. Comparison of the diversity of the vaginal microbiota in HIV-infected and HIV-uninfected women with or without bacterial vaginosis. *J Infect Dis* 2008;198(8):1131–1140. [PubMed: 18717638]
147. Gardner HL, Dukes CD. *Haemophilus vaginalis* vaginitis: a newly defined specific infection previously classified non-specific vaginitis. *Am J Obstet Gynecol* 1955;69(5):962–976. [PubMed: 14361525]
148. Totten PA, Amsel R, Hale J, Piot P, Holmes KK. Selective differential human blood bilayer media for isolation of *Gardnerella (Haemophilus) vaginalis*. *J Clin Microbiol* 1982;15(1):141–147. [PubMed: 6764766]
149. Stackebrandt E, Ludwig W. The importance of using outgroup reference organisms in phylogenetic studies: the *Atopobium* case. *Syst Appl Microbiol* 1994;17:39–43.
150. Hauduroy, P.; Ehringer, G.; Urbain, A.; Guillot, G.; Magrou, J. *Dictionnaire des Bacteries Pathogenes*. Paris: Masson; 1937.
151. Olsen I, Johnson JL, Moore LV, Moore WE. *Lactobacillus uli* sp. nov. and *Lactobacillus rimae* sp. nov. from the human gingival crevice and emended descriptions of *Lactobacillus minutus* and *Streptococcus parvulus*. *Int J Syst Bacteriol* 1991;41(2):261–266. [PubMed: 1854640]
152. Weinberg, M.; Nativelle, R.; Prevot, AR. *Les Microbes Anaerobies*. Paris: Masson; 1937.
153. Collins MD, Wallbanks S. Comparative sequence analyses of the 16S rRNA genes of *Lactobacillus minutus*, *Lactobacillus rimae* and *Streptococcus parvulus*: proposal for the creation of a new genus *Atopobium*. *FEMS Microbiol Lett* 1992;74(2-3):235–240. [PubMed: 1382033]
154. Rodriguez JM, Collins MD, Sjoden B, Falsen E. Characterization of a novel *Atopobium* isolate from the human vagina: description of *Atopobium vaginae* sp. nov. *Int J Syst Bacteriol* 1999;49(Pt 4):1573–1576. [PubMed: 10555338]
155. Bradshaw CS, Tabrizi SN, Fairley CK, Morton AN, Rudland E, Garland SM. The association of *Atopobium vaginae* and *Gardnerella vaginalis* with bacterial vaginosis and recurrence after oral metronidazole therapy. *J Infect Dis* 2006;194(6):828–836. [PubMed: 16941351]
156. De Backer E, Dubreuil L, Brauman M, Acar J, Vanechoutte M. In vitro activity of secnidazole against *Atopobium vaginae*, an anaerobic pathogen involved in bacterial vaginosis. *Clin Microbiol Infect*. 2009
157. Ferris MJ, Maszta A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH. Association of *Atopobium vaginae*, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. *BMC Infect Dis* 2004;4:5. [PubMed: 15018635]
158. Ferris MJ, Maszta A, Martin DH. Use of species-directed 16S rRNA gene PCR primers for detection of *Atopobium vaginae* in patients with bacterial vaginosis. *J Clin Microbiol* 2004;42(12):5892–5894. [PubMed: 15583334]
159. Menard JP, Fenollar F, Henry M, Bretelle F, Raoult D. Molecular quantification of *Gardnerella vaginalis* and *Atopobium vaginae* loads to predict bacterial vaginosis. *Clin Infect Dis* 2008;47(1):33–43. [PubMed: 18513147]
160. Verstraelen H, Verhelst R, Claeys G, Temmerman M, Vanechoutte M. Culture-independent analysis of vaginal microflora: the unrecognized association of *Atopobium vaginae* with bacterial vaginosis. *Am J Obstet Gynecol* 2004;191(4):1130–1132. [PubMed: 15507931]
161. Dewhirst FE, Paster BJ, Tzellas N, Coleman B, Downes J, Spratt DA, et al. Characterization of novel human oral isolates and cloned 16S rDNA sequences that fall in the family *Coriobacteriaceae*: description of *olsenella* gen. nov., reclassification of *Lactobacillus uli* as

- Olsenella uli comb. nov. and description of Olsenella profusa sp. nov. *Int J Syst Evol Microbiol* 2001;51(Pt 5):1797–1804. [PubMed: 11594611]
162. Downes J, Munson MA, Spratt DA, Kononen E, Tarkka E, Jousimies-Somer H, et al. Characterisation of Eubacterium-like strains isolated from oral infections. *J Med Microbiol* 2001;50(11):947–951. [PubMed: 11699590]
 163. Eschenlauer SC, McKain N, Walker ND, McEwan NR, Newbold CJ, Wallace RJ. Ammonia production by ruminal microorganisms and enumeration, isolation, and characterization of bacteria capable of growth on peptides and amino acids from the sheep rumen. *Appl Environ Microbiol* 2002;68(10):4925–4931. [PubMed: 12324340]
 164. Kazor CE, Mitchell PM, Lee AM, Stokes LN, Loesche WJ, Dewhirst FE, et al. Diversity of bacterial populations on the tongue dorsa of patients with halitosis and healthy patients. *J Clin Microbiol* 2003;41(2):558–563. [PubMed: 12574246]
 165. Kumar PS, Griffen AL, Barton JA, Paster BJ, Moeschberger ML, Leys EJ. New bacterial species associated with chronic periodontitis. *J Dent Res* 2003;82(5):338–344. [PubMed: 12709498]
 166. Pybus V, Onderdonk AB. Evidence for a commensal, symbiotic relationship between *Gardnerella vaginalis* and *Prevotella bivia* involving ammonia: potential significance for bacterial vaginosis. *J Infect Dis* 1997;175(2):406–413. [PubMed: 9203662]
 167. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. *Am J Med* 1983;74(1):14–22. [PubMed: 6600371]
 168. Taylor-Robinson D, Morgan DJ, Sheehan M, Rosenstein IJ, Lamont RF. Relation between Gram-stain and clinical criteria for diagnosing bacterial vaginosis with special reference to Gram grade II evaluation. *Int J STD AIDS* 2003;14(1):6–10. [PubMed: 12590785]
 169. Rosenstein IJ, Morgan DJ, Sheehan M, Lamont RF, Taylor-Robinson D. Bacterial vaginosis in pregnancy: distribution of bacterial species in different gram-stain categories of the vaginal flora. *J Med Microbiol* 1996;45(2):120–126. [PubMed: 8683547]
 170. Paster BJ, Boches SK, Galvin JL, Ericson RE, Lau CN, Levanos VA, et al. Bacterial diversity in human subgingival plaque. *J Bacteriol* 2001;183(12):3770–3783. [PubMed: 11371542]
 171. Poco SE Jr, Nakazawa F, Ikeda T, Sato M, Sato T, Hoshino E. *Eubacterium exiguum* sp. nov., isolated from human oral lesions. *Int J Syst Bacteriol* 1996;46(4):1120–1124. [PubMed: 8863445]
 172. Geissdorfer W, Bohmer C, Pelz K, Schoerner C, Frobenius W, Bogdan C. Tuboovarian abscess caused by *Atopobium vaginae* following transvaginal oocyte recovery. *J Clin Microbiol* 2003;41(6):2788–2790. [PubMed: 12791933]
 173. Gundi VA, Desbriere R, La SB. *Leptotrichia amnionii* and the female reproductive tract. *Emerg Infect Dis* 2004;10(11):2056–2057. [PubMed: 16010750]
 174. Hanff PA, Rosol-Donoghue JA, Spiegel CA, Wilson KH, Moore LH. *Leptotrichia sanguinegens* sp. nov., a new agent of postpartum and neonatal bacteremia. *Clin Infect Dis* 1995;20(Suppl 2):S237–S239. [PubMed: 7548563]
 175. Shukla SK, Meier PR, Mitchell PD, Frank DN, Reed KD. *Leptotrichia amnionii* sp. nov., a novel bacterium isolated from the amniotic fluid of a woman after intrauterine fetal demise. *J Clin Microbiol* 2002;40(9):3346–3349. [PubMed: 12202577]
 176. DiGiulio DB, Romero R, Amogan HP, Kusanovic JP, Bik EM, Gotsch F, et al. Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. *PLoS One* 2008;3(8):e3056. [PubMed: 18725970]
 177. DiGiulio DB, Gervasi M, Romero R, Mazaki-Tovi S, Vaisbuch E, Kusanovic JP, et al. Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. *J Perinat Med*. 2010
 178. DiGiulio DB, Romero R, Kusanovic JP, Gomez R, Kim CJ, Seok KS, et al. Prevalence and Diversity of Microbes in the Amniotic Fluid, the Fetal Inflammatory Response, and Pregnancy Outcome in Women with Preterm Pre-Labor Rupture of Membranes. *Am J Reprod Immunol*. 2010

179. Hebb JK, Cohen CR, Astete SG, Bukusi EA, Totten PA. Detection of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. *J Infect Dis* 2004;190(12):2109–2120. [PubMed: 15551209]
180. Lepargneur JP, Dubreuil L, Levy J. Isolation of *Dialister pneumosintes* isolated from a bacteremia of vaginal origin. *Anaerobe* 2006;12(5-6):274–275. [PubMed: 16965925]
181. Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. *BJOG* 2002;109(1):34–43. [PubMed: 11845812]
182. Lamont RF, Hudson EA, Hay PE, Morgan DJ, Modi V, Ison CA, et al. A comparison of the use of Papanicolaou-stained cervical cytological smears with Gram-stained vaginal smears for the diagnosis of bacterial vaginosis in early pregnancy. *Int J STD AIDS* 1999;10(2):93–97. [PubMed: 10215113]
183. Spiegel CA, Amsel R, Holmes KK. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. *J Clin Microbiol* 1983;18(1):170–177. [PubMed: 6193137]
184. Hay PE, Taylor-Robinson D, Lamont RF. Diagnosis of bacterial vaginosis in a gynaecology clinic. *Br J Obstet Gynaecol* 1992;99(1):63–66. [PubMed: 1547176]
185. Ison CA, Hay PE. Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. *Sex Transm Infect* 2002;78(6):413–415. [PubMed: 12473800]
186. Schmidt H, Hansen JG. Diagnosis of bacterial vaginosis by wet mount identification of bacterial morphotypes in vaginal fluid. *Int J STD AIDS* 2000;11(3):150–155. [PubMed: 10726936]
187. Cauci S, Driussi S, Monte R, Lanzafame P, Pitzus E, Quadrifoglio F. Immunoglobulin A response against *Gardnerella vaginalis* hemolysin and sialidase activity in bacterial vaginosis. *Am J Obstet Gynecol* 1998;178(3):511–515. [PubMed: 9539518]
188. Myziuk L, Romanowski B, Johnson SC. BVBlue test for diagnosis of bacterial vaginosis. *J Clin Microbiol* 2003;41(5):1925–1928. [PubMed: 12734228]
189. O'Dowd TC, West RR, Winterburn PJ, Hewlins MJ. Evaluation of a rapid diagnostic test for bacterial vaginosis. *Br J Obstet Gynaecol* 1996;103(4):366–370. [PubMed: 8605135]
190. Thomason JL, Gelbart SM, Wilcoski LM, Peterson AK, Jilly BJ, Hamilton PR. Proline aminopeptidase activity as a rapid diagnostic test to confirm bacterial vaginosis. *Obstet Gynecol* 1988;71(4):607–611. [PubMed: 3353052]
191. Thomason JL, Gelbart SM, James JA, Edwards JM, Hamilton PR. Is analysis of vaginal secretions for volatile organic acids to detect bacterial vaginosis of any diagnostic value? *Am J Obstet Gynecol* 1988;159(6):1509–1511. [PubMed: 3061299]
192. Wolrath H, Forsum U, Larsson PG, Boren H. Analysis of bacterial vaginosis-related amines in vaginal fluid by gas chromatography and mass spectrometry. *J Clin Microbiol* 2001;39(11):4026–4031. [PubMed: 11682525]
193. Fredricks DN, Marrazzo JM. Molecular methodology in determining vaginal flora in health and disease: its time has come. *Curr Infect Dis Rep* 2005;7(6):463–470. [PubMed: 16225785]
194. Doyle LM, McInerney JO, Mooney J, Powell R, Haikara A, Moran AP. Sequence of the gene encoding the 16S rRNA of the beer spoilage organism *Megasphaera cerevisiae*. *J Ind Microbiol* 1995;15(2):67–70. [PubMed: 7576462]
195. Ziola B, Gee L, Berg NN, Lee SY. Serogroups of the beer spoilage bacterium *Megasphaera cerevisiae* correlate with the molecular weight of the major EDTA-extractable surface protein. *Can J Microbiol* 2000;46(2):95–100. [PubMed: 10721476]
196. Haggerty CL, Totten PA, Ferris M, Martin DH, Hoferka S, Astete SG, et al. Clinical characteristics of bacterial vaginosis among women testing positive for fastidious bacteria. *Sex Transm Infect* 2009;85(4):242–248. [PubMed: 19004865]
197. Ness RB, Hillier SL, Richter HE, Soper DE, Stamm C, McGregor J, et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. *Obstet Gynecol* 2002;100(4):765. [PubMed: 12383547]
198. Hanson JM, McGregor JA, Hillier SL, Eschenbach DA, Kreutner AK, Galask RP, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. *J Reprod Med* 2000;45(11):889–896. [PubMed: 11127100]

199. Livengood CH III, Soper DE, Sheehan KL, Fenner DE, Martens MG, Nelson AL, et al. Comparison of once-daily and twice-daily dosing of 0.75% metronidazole gel in the treatment of bacterial vaginosis. *Sex Transm Dis* 1999;26(3):137–142. [PubMed: 10100770]
200. Livengood CH III, McGregor JA, Soper DE, Newton E, Thomason JL. Bacterial vaginosis: efficacy and safety of intravaginal metronidazole treatment. *Am J Obstet Gynecol* 1994;170(3):759–764. [PubMed: 8141197]
201. Nyirjesy P, McIntosh MJ, Steinmetz JI, Schumacher RJ, Joffrion JL. The effects of intravaginal clindamycin and metronidazole therapy on vaginal mobiluncus morphotypes in patients with bacterial vaginosis. *Sex Transm Dis* 2007;34(4):197–202. [PubMed: 17179772]
202. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. *J Infect Dis* 2006;193(11):1478–1486. [PubMed: 16652274]
203. Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. *Am J Obstet Gynecol* 2004;191(6):1898–1906. [PubMed: 15592270]
204. Sobel JD, Ferris D, Schwabke J, Nyirjesy P, Wiesenfeld HC, Peipert J, et al. Suppressing antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. *Am J Obstet Gynecol* 2006;194(5):1283–1289. [PubMed: 16647911]
205. Agnew KJ, Hillier SL. The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. *Sex Transm Dis* 1995;22(5):269–273. [PubMed: 7502179]
206. Devillard E, Burton JP, Reid G. Complexity of vaginal microflora as analyzed by PCR denaturing gradient gel electrophoresis in a patient with recurrent bacterial vaginosis. *Infect Dis Obstet Gynecol* 2005;13(1):25–31. [PubMed: 16040324]
207. Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN. Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. *Ann Intern Med* 2008;149(1):20–28. [PubMed: 18591634]
208. Hale LP, Swidsinski A, Mendling W. Bacteria associated with bacterial vaginosis. *N Engl J Med* 2006;354(2):202–203. [PubMed: 16407518]
209. Swidsinski A, Mendling W, Loening-Baucke V, Swidsinski S, Dorffle Y, Scholze J, et al. An adherent *Gardnerella vaginalis* biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. *Am J Obstet Gynecol* 2008;198(1):97–6. [PubMed: 18005928]
210. Kim M, Kim G, Romero R, Shim SS, Kim EC, Yoon BH. Biovar diversity of *Ureaplasma urealyticum* in amniotic fluid: distribution, intrauterine inflammatory response and pregnancy outcomes. *J Perinat Med* 2003;31(2):146–152. [PubMed: 12747231]
211. Bujold E, Morency AM, Rallu F, Ferland S, Tetu A, Duperron L, et al. Bacteriology of amniotic fluid in women with suspected cervical insufficiency. *J Obstet Gynaecol Can* 2008;30(10):882–887. [PubMed: 19038071]
212. Yoon BH, Romero R, Lim JH, Shim SS, Hong JS, Shim JY, et al. The clinical significance of detecting *Ureaplasma urealyticum* by the polymerase chain reaction in the amniotic fluid of patients with preterm labor. *Am J Obstet Gynecol* 2003;189(4):919–924. [PubMed: 14586326]
213. Yoon BH, Romero R, Kim M, Kim EC, Kim T, Park JS, et al. Clinical implications of detection of *Ureaplasma urealyticum* in the amniotic cavity with the polymerase chain reaction. *Am J Obstet Gynecol* 2000;183(5):1130–1137. [PubMed: 11084554]
214. DiGiulio DB, Gervasi M, Romero R, Vaisbuch E, Mazaki-Tovi S, Kusanovic JP, et al. Microbial invasion of the amniotic cavity in pregnancies with small-for-gestational-age fetuses. *J Perinat Med*. 2010
215. Bearfield C, Davenport ES, Sivapathasundaram V, Allaker RP. Possible association between amniotic fluid micro-organism infection and microflora in the mouth. *BJOG* 2002;109(5):527–533. [PubMed: 12066942]
216. Creasy RK, Gummer BA, Liggins GC. System for predicting spontaneous preterm birth. *Obstet Gynecol* 1980;55(6):692–695. [PubMed: 7383454]
217. Verstraelen H, Verhelst R, Claeys G, De BE, Temmerman M, Vanechoutte M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that *L. crispatus* promotes the stability

of the normal vaginal microflora and that *L. gasseri* and/or *L. iners* are more conducive to the occurrence of abnormal vaginal microflora. *BMC Microbiol* 2009;9:116. [PubMed: 19490622]




Figure 1.
The Human Microbiome Project

Table 1Obligately Homofermentative Species Within the *Lactobacillus acidophilus* Complex.

Lactobacillus acidophilus
Lactobacillus amylolyticus
Lactobacillus amylovorus
Lactobacillus crispatus
Lactobacillus gallinarium
Lactobacillus gasseri
Lactobacillus iners
Lactobacillus jensenii
Lactobacillus johnsoni

Table 2

Previously unfamiliar vaginal organisms identified by molecular based techniques

<i>Atopobium vaginae</i> ,
BV associated bacteria [BVAB]-1, BVAB-2, and BVAB-3 in the order <i>Clostridiales</i> ,
Megasphaera spp
Leptotrichia spp
Dialister spp
Chloroflexi spp
Olsenella spp
Streptobacillus spp
Shuttleworthia spp
Porphyromonas asaccharolytica

A bacterium distantly related to *Eggerthella hongkongensis* (92% sequence similarity)

Table 3

The sensitivities and specificities for individual or combinations of organisms for the diagnosis of BV using Amsel criteria or Nugent score

Study	Diagnosis of BV	Organism	Sensitivity	Specificity
Frederick et al ⁵³	Amsel	BVAB-1	40.7	97.8
Frederick et al ⁵³	Amsel	BVAB-2	88.9	95.7
Frederick et al ⁵³	Amsel	BVAB-3	40.7	97.8
Frederick et al ⁵³	Amsel	<i>G.vaginalis</i>	100	41.3
Frederick et al ⁵³	Amsel	BVAB-1 and BVAB-3	33.3	100
Frederick et al ⁵³	Amsel	BVAB-2 or <i>Megasphaera</i>	100	91.3
Fredericks et al ⁷²	Amsel	Either <i>Megasphaera</i> or BVAB-1, BVAB-2, or BVAB-3	99	89
Fredericks et al ⁷²	Nugent	Either <i>Megasphaera</i> or BVAB-1, BVAB-2, or BVAB-3	95.9	95.7

BVAB = bacterial vaginosis associated bacteria

Table 4
Quantification of vaginal organisms for the production of BV using Nugent score.¹⁵⁹

Organism	Threshold Quantification (DNA copies/mL)	Sensitivity	Specificity	NPV	PPV	ROC AUC
<i>A. vaginae</i>	$\geq 10^8$	90	99	99	95	0.964
<i>G. vaginalis</i>	$\geq 10^9$	50	100	94	100	0.946
<i>M. curtisii</i>	$\geq 10^5$	45	100	-	-	0.798
<i>M. hominis</i>	$\geq 10^6$	30	98	-	-	0.691

NPV = Negative predictive value

PPV = Positive predictive value

ROC = Receiver operating characteristic

AUC = Area under the curve (The closer the AUC comes is to 1.0, the better the bacterial count predicts BV)